GammaPod Introduces Revolutionary Breast Cancer Treatment in Europe with Single Session Therapy
In a remarkable leap in breast cancer care, GammaPod has officially made its debut in Europe, promising a new standard for treatment efficacy and patient comfort. This groundbreaking technology, spearheaded by Tema Sinergie SpA from Faenza, Italy, introduces an advanced technique known as Stereotactic Partial Breast Irradiation (S-PBI), enabling oncologists to deliver exceptionally high radiation doses to tumors in a single session, a stark contrast to traditional methods that often require multiple treatment fractions.
The GammaPod system, innovated by Cedric Yu, a respected physicist and emeritus professor at the University of Maryland, has been meticulously designed to solely target breast cancer. Unlike conventional radiation therapy machines that cater to multiple forms of cancer across various body parts, GammaPod zeroes in on breast tumors. This specialized capacity allows for precision in the delivery of large doses while significantly minimizing radiation exposure to surrounding healthy tissues. The result is a hormonal reduction in the adverse side effects typically associated with wider radiation treatments.
The implications of such a non-invasive treatment approach are profound. Patients, who in the past faced the discomfort of several sessions, are now offered a streamlined therapeutic procedure—one that not only promises effectiveness but aims to enhance overall quality of life. As evidenced by clinical trials conducted at Udine’s Santa Maria della Misericordia Hospital, published in the highly regarded Red Journal, the GammaPod demonstrates not only safety but exceptional efficacy in preoperative breast cancer therapy. The study highlights a significant drop in the Ki-67 cell proliferation index, a vital marker indicating tumor response to radiation therapy.
Dr. Marco Trovò, the head of radiation therapy at the Udine Hospital, extols the unique advantages of GammaPod. "With the ability to administer considerable radiation doses effectively in just one session, we are witnessing a considerable biological response in tumors, evidenced by the marked decrease in Ki-67 levels,” he affirms.
The significance of GammaPod's launch will reach an international audience on May 5, 2025, at the Satellite Symposium titled 'Reducing the Impact of Breast Cancer', which Tema Sinergie is hosting during the ESTRO 2025 Congress in Vienna. Esteemed professionals, including Prof. Cedric Yu, will present on the technology's features, while Dr. Trovò and Prof. Asal Rahimi will discuss the outcomes of their respective clinical studies. The session promises to spotlight the transformative potential of GammaPod in the oncology landscape.
Tema Sinergie's commitment to introducing GammaPod across Europe underscores an essential stride towards improving cancer patient care. This endeavor heralds a pivotal change in the battle against breast cancer, emphasizing the importance of global collaboration in the delivery of cutting-edge therapeutic solutions. As GammaPod gives new hope and treatment options to patients, it stands as a vital component in the ongoing effort to enhance the fight against breast cancer and improve survival outcomes. In conclusion, GammaPod represents a fusion of innovative technology and compassionate care, poised to redefine the future of breast cancer treatment in Europe and beyond.
The GammaPod system, innovated by Cedric Yu, a respected physicist and emeritus professor at the University of Maryland, has been meticulously designed to solely target breast cancer. Unlike conventional radiation therapy machines that cater to multiple forms of cancer across various body parts, GammaPod zeroes in on breast tumors. This specialized capacity allows for precision in the delivery of large doses while significantly minimizing radiation exposure to surrounding healthy tissues. The result is a hormonal reduction in the adverse side effects typically associated with wider radiation treatments.
The implications of such a non-invasive treatment approach are profound. Patients, who in the past faced the discomfort of several sessions, are now offered a streamlined therapeutic procedure—one that not only promises effectiveness but aims to enhance overall quality of life. As evidenced by clinical trials conducted at Udine’s Santa Maria della Misericordia Hospital, published in the highly regarded Red Journal, the GammaPod demonstrates not only safety but exceptional efficacy in preoperative breast cancer therapy. The study highlights a significant drop in the Ki-67 cell proliferation index, a vital marker indicating tumor response to radiation therapy.
Dr. Marco Trovò, the head of radiation therapy at the Udine Hospital, extols the unique advantages of GammaPod. "With the ability to administer considerable radiation doses effectively in just one session, we are witnessing a considerable biological response in tumors, evidenced by the marked decrease in Ki-67 levels,” he affirms.
The significance of GammaPod's launch will reach an international audience on May 5, 2025, at the Satellite Symposium titled 'Reducing the Impact of Breast Cancer', which Tema Sinergie is hosting during the ESTRO 2025 Congress in Vienna. Esteemed professionals, including Prof. Cedric Yu, will present on the technology's features, while Dr. Trovò and Prof. Asal Rahimi will discuss the outcomes of their respective clinical studies. The session promises to spotlight the transformative potential of GammaPod in the oncology landscape.
Tema Sinergie's commitment to introducing GammaPod across Europe underscores an essential stride towards improving cancer patient care. This endeavor heralds a pivotal change in the battle against breast cancer, emphasizing the importance of global collaboration in the delivery of cutting-edge therapeutic solutions. As GammaPod gives new hope and treatment options to patients, it stands as a vital component in the ongoing effort to enhance the fight against breast cancer and improve survival outcomes. In conclusion, GammaPod represents a fusion of innovative technology and compassionate care, poised to redefine the future of breast cancer treatment in Europe and beyond.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.